Navigation Links
Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
Date:2/26/2009

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, Missouri this fall.

"The last six months have been very exciting," said Marc Buntaine, CEO. "Still River has achieved all of the component milestones that bring us to system integration and delivery." Proton therapy, widely regarded as the next evolutionary step in the radiation treatment of cancer, has seen unprecedented interest from the radiation oncology and patient communities in recent years. However, the large size and high cost of existing proton therapy systems have made it difficult for the average hospital to add this powerful tool to their cancer fighting arsenal.

The heart of the Monarch250, a superconducting magnet developed in an industrial and academic partnership with the Massachusetts Institute of Technology, has now tested operational and stable at its full design current "This magnet sets a record for magnetic field strength used in a high energy cyclotron. The cyclotron built around this magnet will be the most compact source for proton therapy available today." said Dr. Kenneth Gall, founder and Chief Technology Officer. "All of the Monarch250 sub-systems are now in the final phases of manufacturing and will be ready to ship to our first customers for installation later this year".

Still River's Monarch250 proton therapy system, a unique and compact machine, was developed to provide proton therapy at a greatly reduced cost and size. In addition, Still River Systems has incorporated the latest advancements in radiation therapy patient management with its innovative accelerator technology, including a robotic couch for patient positioning, dedicated proton therapy treatment planning, cone beam CT imaging, and motion management. All of these clinical systems have been integrated within the Monarch250 platform. "Our goal is to provide our customers with a fully integrated, turnkey proton therapy solution with the most advanced clinical systems for patient management" said Dr. Skip Rosenthal, Vice President of Clinical Systems. "Integrating these key radiation therapy technologies is critical to ease of use in a clinical setting."

Still River Systems first installation sites, Barnes Jewish Hospital in St. Louis, Missouri and Robert Wood Johnson University Hospital in New Jersey, have begun construction for the new facilities that will house the first Monarch250 systems in the United States.

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients' access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. This system has not yet been cleared by the FDA for commercial use in clinical therapy. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.StillRiverSystems.com.


'/>"/>
SOURCE Still River Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
4. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
5. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
6. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
10. Stem Cell Regeneration Repairs Congenital Heart Defect
11. TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):